First AD

Second AD

Dr Chelsee Jensen Talks About the Mayo Clinic's Approach to Expanding Biosimilar Use

Dr Eric Tichy Dives Into Why the Mayo Clinic Chose to Study Adoption Among Oncology Biosimilars

Dr Eric Tichy: Why the Mayo Clinic Did Not Cover Biosimilars, Reference Products at Parity

Dr Chelsee Jensen Explores the Present and Future Impacts of COVID-19 on Biosimilar Adoption

Interviews

News

Oncology

Practice

Conference

Eric Tichy, PharmD, MBA, vice chair of pharmacy formulary at the Mayo Clinic Health System, offered insight into why his practice did not cover biosimilars at parity with reference products in his recent study on biosimilar adoption.

Chelsee Jensen, PharmD, and Eric Tichy, PharmD, MBA, who coauthored a paper on the Mayo Clinic's success with implementing biosimilars, discuss their study and how their practice is expected to evolve to improve its approach.

Dr Chelsee Jensen and Dr Eric Tichy Discuss the Mayo Clinic's Success With Biosimilar Adoption